Scots say yes to cancer drugs after patients have their say
This article was originally published in Scrip
Using a new process that involves greater patient input, Scotland's health technology appraisal body, the Scottish Medicines Consortium, has okayed for use on the local NHS three anticancers that England has so far largely rejected for use on its NHS. Ariad's Iclusig (ponatinib), Boehringer Ingelheim's Vargatef (nintedanib) and Bayer's Stivarga (regorafenib) have all been given the green light in Scotland.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.